A randomized, double-blind, phase 2 trial of paclitaxel plus bevacizumab and enzastaurin versus paclitaxel plus bevacizumab and placebo for locally recurrent or metastatic breast cancer
Phase of Trial: Phase II
Latest Information Update: 25 Nov 2014
At a glance
- Drugs Enzastaurin (Primary) ; Bevacizumab; Paclitaxel
- Indications Advanced breast cancer; Male breast cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 12 Aug 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 12 Aug 2008 Actual patient number is changed from 120 to 2 as reported by ClinicalTrials.gov.
- 12 Aug 2008 Actual end date is 1 March 2008 as reported by ClinicalTrials.gov.